August 19, 2020 -- Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual groundbreaking ceremony on August 19 for its Advanced Therapies Innovation Center construction project in Texas.
The $55 million, 60,000-sq-ft facility is being constructed in College Station and will house dedicated process development and innovation laboratories. The labs will have biosafety level 2 capabilities with advanced upstream, downstream, and analytical development technologies. The building is part of a 22-acre parcel acquired by Fujifilm in June 2020.
The facility will triple the company's advanced therapies and process development capabilities and help the company provide end-to-end gene therapy solutions from preclinical to commercial launch. It is expected to be operational in the fall of 2021.